| 11/10/2026 7:03 AM | Tyra Biosciences (1863127) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/10/2026 7:11 AM | Tyra Biosciences (1863127) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/27/2026 4:25 PM | BlackRock, Inc. (2012383) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 09/21/2026 4:21 PM | BIOTECHNOLOGY VALUE FUND L P (918923) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G | |
| 09/17/2026 6:25 PM | Fuhrman Alan (1303521) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/17/2026 6:26 PM | Rueb Yuliya (2125370) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/17/2026 6:29 PM | Harris Todd (1711463) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/17/2026 3:31 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund, L.P. (1780117) Reporting Shah Rajeev M. (1619841) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/17/2026 3:32 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13D/A | |
| 09/17/2026 3:06 PM | Paradigm Biocapital Advisors LP (1855655) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G | |
| 09/14/2026 5:33 AM | Tyra Biosciences (1863127) Subject | Form FWP | |
Get the Latest News and Ratings for TYRA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/14/2026 5:02 AM | Tyra Biosciences (1863127) Filer | Form S-3ASR | |
| 09/11/2026 3:30 PM | Tyra Biosciences (1863127) Issuer Verjee Rehan (1880637) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/09/2026 6:10 AM | Tyra Biosciences (1863127) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 3:44 PM | NEXTECH VI ONCOLOGY SCSP (1804218) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 08/14/2026 7:24 AM | FARALLON CAPITAL MANAGEMENT, L.L.C. (909661) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 08/04/2026 3:42 PM | Tyra Biosciences (1863127) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/04/2026 3:04 PM | Tyra Biosciences (1863127) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/30/2026 10:18 AM | BlackRock, Inc. (2012383) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G | |
| 06/26/2026 3:59 PM | NEXTECH VI ONCOLOGY SCSP (1804218) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/01/2026 4:45 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund, L.P. (1780117) Reporting Shah Rajeev M. (1619841) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/01/2026 3:16 PM | NEXTECH VI ONCOLOGY SCSP (1804218) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/15/2026 11:50 AM | JANUS HENDERSON GROUP PLC (1274173) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 05/14/2026 3:56 PM | Harris Todd (1711463) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 05/13/2026 7:00 AM | Tyra Biosciences (1863127) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/13/2026 7:03 AM | Tyra Biosciences (1863127) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/12/2026 4:33 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/12/2026 7:54 AM | Farallon Capital Partners, L.P. (1175707) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 05/07/2026 3:30 PM | Rueb Yuliya (2125370) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:30 PM | Ashar Bhavesh (1849740) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:30 PM | Harris Todd (1711463) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:30 PM | Fuhrman Alan (1303521) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:30 PM | Tyra Biosciences (1863127) Issuer Warner Douglas J (1941311) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/24/2026 3:15 PM | Canaan XI L.P. (1712417) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G/A | |
| 04/20/2026 3:30 PM | Dable Habib J (1690773) Reporting Tyra Biosciences (1863127) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/20/2026 3:31 PM | Dable Habib J (1690773) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/17/2026 7:08 AM | Tyra Biosciences (1863127) Filer | Form DEF 14A | |
| 04/17/2026 7:10 AM | Tyra Biosciences (1863127) Filer | Form DEFA14A | |
| 04/17/2026 7:11 AM | Tyra Biosciences (1863127) Filer | Form ARS | |
| 04/17/2026 7:02 AM | Tyra Biosciences (1863127) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/13/2026 3:44 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Pentagon magnet restrictions take effect January 1, 2027 (Ad) A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production.
The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing.
The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027. Read the full breakdown of the proposed Army rare earth agreement and the company behind it. |
| 04/07/2026 12:33 PM | FMR LLC (315066) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G | |
| 04/02/2026 3:38 PM | Rueb Yuliya (2125370) Reporting Tyra Biosciences (1863127) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/27/2026 3:44 PM | KAPLAN GILLA (1247024) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/25/2026 4:36 PM | KAPLAN GILLA (1247024) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/12/2026 4:42 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/06/2026 3:28 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13D/A | |
| 02/20/2026 7:14 AM | Farallon Capital Partners, L.P. (1175707) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G | |
| 02/13/2026 3:30 PM | Harris Todd (1711463) Filed by Tyra Biosciences (1863127) Subject | Form SCHEDULE 13G | |
| 02/13/2026 3:30 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/20/2026 3:30 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 4:38 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/19/2025 8:00 PM | MORE ROBERT J (1207792) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 3:30 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 5:16 PM | Ashar Bhavesh (1849740) Reporting Tyra Biosciences (1863127) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 12/01/2025 5:17 PM | Ashar Bhavesh (1849740) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 7:00 AM | Tyra Biosciences (1863127) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/25/2025 4:00 PM | MORE ROBERT J (1207792) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/21/2025 3:26 PM | Alta Partners NextGen Fund II, L.P. (1768658) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/19/2025 6:30 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/18/2025 4:04 PM | Bensen Daniel (1880946) Reporting Tyra Biosciences (1863127) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |